Exploring the Therapeutic Potential of Microbiome-Derived Postbiotics in Chronic Inflammatory Disorders

Abstract

Background: Chronic inflammatory diseases, including rheumatoid arthritis (RA), Crohn’s disease (CD), and ulcerative colitis (UC) are associated with ongoing immune dysregulation and poor response to traditional treatment. Recently, postbiotics as non-living microbial products and metabolites have become promising therapeutic options due to these characteristics of stability, safety, and immunomodulatory. Objective: This paper assessed the therapeutic potential of postbiotics to reduce systemic inflammation and clinical outcome in patients with RA, CD, and UC. Methods: This study used a quantitative experimental design to study the therapeutic effects of postbiotics on inflammatory biomarkers and clinical responses in people with rheumatoid arthritis (RA), Crohn's disease (CD), and ulcerative colitis (UC). A total of 200 participants were purposively selected in three tertiary educational institutions, and included 70 RA, 65 CD, and 65 UC patients, who all satisfied the accepted diagnostic criteria (ACR/EULAR RA; ECCO guidelines CD and UC). Findings: Statistically significant improvements in CRP (12.3 ± 4.2 → 6.1 ± 3.0 mg/L), IL-6 (18.4 6.5 → 10.7 4.2 pg/mL) and TNF-a (22.5 7.1 8.1) were achieved by the post biotic supplementation (all p 0.001). There were also improved clinical outcomes, with a significant reduction in DAS28, CDAI and Mayo indexes in comparison with placebo (p 0.001). Conclusion: Postbiotics showed sound anti-inflammatory and clinically relevant improvements in RA, CD, and UC populations. Their inherent stability, safety profile, and reproducibility present their potential as adjunctive therapies to control chronic inflammatory diseases. Long-term effectiveness and clinical usage should be optimized by prospective large-scale trials to validate long-term effectiveness.